Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout

Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including a background in multiple sclerosis and central nervous system markets.